-
公开(公告)号：KR100970911B1
公开(公告)日：2010-07-20
申请号：KR1020070130121
申请日：2007-12-13
Applicant: 재단법인서울대학교산학협력재단
Inventor： 김대덕
Abstract: 본 발명은 피부 투과용 항진균성 반고형 외용제 및 이의 제조방법에 관한 것으로, 보다 상세하게는 플루코나졸 및 보리코나졸로 이루어진 군에서 선택된 1종 이상의 트리아졸계 항진균제; 물과 혼화가 가능한 1종 이상의 용해제; 인지질; 및 물을 함유하는 반고형 외용제에 관한 것이며, 추가로 수용성 점증제를 더 함유할 수 있는 반고형 외용제에 관한 것이다.
항진균제, 반고형, 외용제-
公开(公告)号：KR1020090062707A
公开(公告)日：2009-06-17
申请号：KR1020070130121
申请日：2007-12-13
Applicant: 재단법인서울대학교산학협력재단
Inventor： 김대덕
CPC classification number: A61K47/24 , A61K9/0014 , A61K9/06 , A61K9/08 , A61K9/12 , A61K31/41 , A61K31/506 , A61K2121/00
Abstract: An antifungal liposomal external agent for skin penetration, which has liposome dispersed type is provided to apply triazole based antifungal agent into topical skin, prevent the side effect of whole body and heighten the skin penetration. A liposomal external agent comprises 0.01-10 weight% of triazole based antifungal agent, 0.1-60 weight% of dissolution agent, 0.1-30 weight% of phospholipid and remaining amount of water. The liposomal external agent is used in a form of liquid, spray, liniment agent or aerosol. A method for manufacturing the liposomal external agent comprises: a step of resolving the triazole based antifungal agent with dissolution agent; a step of resolving phospholipid in dissolution agent; a step of stirring the triazole based antifungal agent in phospholipid solution to produce common solvent; and a step of stirring and adding common solvent solution in water or aqueous phase.
Abstract translation: 提供具有脂质体分散型的用于皮肤渗透的抗真菌脂质体外用剂，以将三唑类抗真菌剂施用于局部皮肤，防止全身的副作用并提高皮肤渗透性。 脂质体外用剂包含0.01-10重量％的三唑类抗真菌剂，0.1-60重量％的溶解剂，0.1-30重量％的磷脂和剩余量的水。 脂质体外用剂以液体，喷雾剂，搽剂或气雾剂的形式使用。 制备脂质体外用剂的方法包括：用溶解剂分解三唑类抗真菌剂的步骤; 解决溶剂中磷脂的一个步骤; 在磷脂溶液中搅拌三唑类抗真菌剂以产生常见溶剂的步骤; 以及将常规溶剂溶液搅拌并添加到水或水相中的步骤。
-
公开(公告)号：KR100910848B1
公开(公告)日：2009-08-06
申请号：KR1020070093307
申请日：2007-09-13
Applicant: 재단법인서울대학교산학협력재단
IPC: A61K47/48 , A61K31/445 , A61K31/75
Abstract: 본 발명은 활성성분으로서 항히스타민제를 비롯한 알러지성 비염 치료약물을 함유하는 비강 분무용 마이크로스피어 및 이의 제조방법에 관한 것으로, 알러지성 비염 치료약물 10-20 중량%, 점착성 폴리머 60-80 중량%, 방출제어제 1-10 중량% 및 담즙산염 1-15 중량%로 구성된 본 발명의 마이크로스피어는 항히스타민제를 비롯한 알러지성 비염 치료약물의 쓴맛 차폐성을 갖고 경구투여가 곤란한 환자에게 약물을 손쉽게 투여할 수 있고, 약동학적 파라미터, 적어도 통상적인 항히스타민제를 비롯한 알러지성 비염 치료약물 경구제제에서 얻어지는 것과 유사한 생물학적 동등성을 얻을 수 있기 때문에 비강 분무제제로 사용하여 바람직한 약효를 나타낼 수 있다.
항히스타민제, 알러지성 비염, 비강 분무, 마이크로스피어, 담즙산염-
Patent Agency Ranking
公开(公告)号：KR1020070108062A
公开(公告)日：2007-11-08
申请号：KR1020070042611
申请日：2007-05-02
Applicant: 재단법인서울대학교산학협력재단 , 주프로스테믹스
IPC: C08B37/08
CPC classification number: C08B37/0072 , A61K35/30 , A61K35/32 , A61K35/34 , A61K35/545 , C08J9/28 , C08J2201/026 , C08J2201/0484 , C08J2205/022 , C08J2305/08 , C12N5/0068 , C12N2533/80 , C12N2537/00 , C12N2537/10
Abstract: A method for preparing a porous hyaluronic acid sponge for a cell delivery system is provided to produce a porous hyaluronic acid sponge capable of controlling pore size thereof so as to cultivate cells well. A method for preparing a porous hyaluronic acid sponge includes the steps of: (S101) dissolving a hyaluronic acid in an aqueous sodium hydroxide solution; (S102) adding an epoxy-based crosslinking agent to the aqueous sodium hydroxide solution containing hyaluronic acid, and then homogenizing the obtained hyaluronic acid solution; (S103) hydrogelling the homogenized hyaluronic acid solution; (S104) washing the hyaluronic acid hydrogel with ultrapure water; (S105) swelling the washed hyaluronic acid hydrogel to acquire porosity; and (S106) freeze-drying the hyaluronic acid hydrogel to obtain a porous hyaluronic acid sponge.
Abstract translation: 提供了一种制备用于细胞递送系统的多孔透明质酸海绵的方法，以制备能够控制其孔径以便良好培养细胞的多孔透明质酸海绵。 制备多孔透明质酸海绵的方法包括以下步骤：（S101）将透明质酸溶解在氢氧化钠水溶液中; （S102）向含有透明质酸的氢氧化钠水溶液中添加环氧类交联剂，然后均化所得透明质酸溶液; （S103）使匀化的透明质酸溶液水凝; （S104）用超纯水洗涤透明质酸水凝胶; （S105）溶解洗涤后的透明质酸水凝胶以获得孔隙度; 和（S106）冷冻干燥透明质酸水凝胶，得到多孔透明质酸海绵。
-
公开(公告)号：KR100891373B1
公开(公告)日：2009-04-02
申请号：KR1020070042611
申请日：2007-05-02
Applicant: 재단법인서울대학교산학협력재단 , 주프로스테믹스
IPC: C08B37/08
CPC classification number: C08B37/0072 , A61K35/30 , A61K35/32 , A61K35/34 , A61K35/545 , C08J9/28 , C08J2201/026 , C08J2201/0484 , C08J2205/022 , C08J2305/08 , C12N5/0068 , C12N2533/80 , C12N2537/00 , C12N2537/10
Abstract: Provided is a preparation method of a porous hyaluronic acid sponge comprising the steps of: dissolving hyaluronic acid in an aqueous sodium hydroxide solution; adding an epoxy-based crosslinking agent to the resultant aqueous sodium hydroxide solution in which hyaluronic acid is dissolved and homogenizing the hyaluronic acid solution; hydrogelating the homogenized hyaluronic acid solution; washing the hydrogelated hyaluronic acid hydrogel with ultrapure water; swelling the washed hyaluronic acid hydrogel to attain porosity; and freeze-drying the hyaluronic acid hydrogel to obtain a porous hyaluronic acid sponge.
-
公开(公告)号：KR1020090028045A
公开(公告)日：2009-03-18
申请号：KR1020070093307
申请日：2007-09-13
Applicant: 재단법인서울대학교산학협력재단
IPC: A61K47/48 , A61K31/445 , A61K31/75
CPC classification number: A61K47/36 , A61K9/0043 , A61K9/12 , A61K31/445 , A61K47/28 , A61K2121/00 , Y10S424/81
Abstract: A microsphere for nasal spray is provided to remove bitter taste from allergic rhinitis therapeutic agent including antihistaminic agent and to prescribe easily drug to patients that oral administration is difficult and to obtain bioequivalence similar to oral preparations from allergic rhinitis therapeutic agent including normal antihistaminic agent. A microsphere for nasal spray comprises allergic rhinitis therapeutic agent 10-20 weight%, adhesive polymer 60-80 weight%, emission controlling agent 1-10 weight% and bile salts 1-15 weight%. The adhesive polymer is one selected from a group consisting of hyaluronic acid, gelatin, collagen, chitosan, polyacrylic acid and cellulose derivative. The emission controlling agent is one selected from a group consisting of polyethylene glycol, mannitol and Bovine Serum albumin.
Abstract translation: 提供用于鼻喷雾的微球，以消除包括抗组胺剂在内的过敏性鼻炎治疗剂的苦味，并且对口服难以治疗的患者开药容易，并获得与包括正常抗组胺剂在内的过敏性鼻炎治疗剂的口服制剂类似的生物等效性。 用于鼻喷雾剂的微球包括10-20重量％的过敏性鼻炎治疗剂，60-80重量％的粘合剂聚合物，1-10重量％的排泄控制剂和1-15重量％的胆汁盐。 粘合剂聚合物选自透明质酸，明胶，胶原，壳聚糖，聚丙烯酸和纤维素衍生物。 排放控制剂是选自聚乙二醇，甘露糖醇和牛血清白蛋白的一种。
-
公开(公告)号：KR100866979B1
公开(公告)日：2008-11-05
申请号：KR1020070028806
申请日：2007-03-23
Applicant: 재단법인서울대학교산학협력재단
Abstract: 본 발명은 이트라코나졸을 오일상인 벤질알코올에 용해시킨 마이크로이멀젼계 하이드로겔에 관한 것으로, 보다 상세하게는 이트라코나졸을 마이크로이멀젼계 하이드로겔로 제제화하여 진균력이 높지만 경구투여시 간독성과 위장장애가 심한 이트라코나졸을 국소 피부에 적용함으로써 부작용을 줄이고 진균 치료효과를 높인 마이크로이멀젼계 하이드로겔 및 이의 제조방법에 관한 것이다.
이트라코나졸, 벤질알코올, 마이크로이멀젼, 하이드로겔-
公开(公告)号：KR1020080086736A
公开(公告)日：2008-09-26
申请号：KR1020070028806
申请日：2007-03-23
Applicant: 재단법인서울대학교산학협력재단
CPC classification number: A61K47/10 , A61K9/0014 , A61K9/06 , A61K9/1075 , A61K31/496 , A61K2121/00
Abstract: A microemulsion-based hydrogel comprising itraconazole is provided to reduce side effects of itraconazole including liver toxicity and stomach disorder caused by oral administration by application into the local skin, and increase antifungal activity of itraconazole. A microemulsion-based hydrogel comprises itraconazole dissolved in benzyl alcohol as an oil phase, and further comprises surfactant selected from diethyleneglycolmonoether, ethanol and phospholipid and gelating agent selected from carbopol and xanthan gum. A preparation method of the microemulsion-based hydrogel comprises the steps of: solubilizing itraconazole in benzyl alcohol; adding surfactant into the solution to prepare an oil phase; and adding an aqueous phase containing carbopol and xanthan gum into the oil phase.
Abstract translation: 提供包含伊曲康唑的基于微乳液的水凝胶，以减少伊曲康唑的副作用，包括通过施用于局部皮肤通过口服施用引起的肝毒性和胃病，并增加伊曲康唑的抗真菌活性。 基于微乳液的水凝胶包含溶解在苯甲醇中的伊曲康唑作为油相，并且还包含选自二乙二醇单醚，乙醇和磷脂的表面活性剂和选自卡波姆和黄原胶的凝胶剂。 微乳液型水凝胶的制备方法包括以下步骤：将伊曲康唑溶解在苄醇中; 向溶液中加入表面活性剂以制备油相; 并将含有卡波姆和黄原胶的水相加入到油相中。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.034 seconds)
